Cryptosporidium sp. is a pathogen that causes gastroenteritis and may increase mortality and morbidity in immunocompromised patients. Cryptosporidium became widely recognized as a human pathogen. Diarrhea is a common problem in AIDS patients and about 30%–60% of patients in developed countries and 90% in developing countries experience diarrhea. This study was conducted using a systematic review design. Two articles with cohort design and two with case report design were selected based on the eligibility criteria. Three of these studies used a combination of nitazoxanide with azithromycin as an intervention, one in cohort design and two in case report design. One cohort study used a nitazoxanide and fluoroquinolone combination as an intervention. 54 samples participated in this study were post kidney transplantation patients and one sample was with acute lymphoblastic leukemia (ALL). Nitazoxanide and fluoroquinolone combination is a better therapy for cryptosporidiosis in immunocompromised patients compared to nitazoxanide and azithromycin combination. The(OR) for stool clearance was significantly lower with nitazoxanide alone compared to that of nitazoxanide and fluoroquinolone (OR: 0.65, 95% CI: 0.34, 0.92, P= 0.01), and the OR for diarrhea stopped was significantly lower with nitazoxanide alone compared to that of nitazoxanide and fluoroquinolone (OR: 0.45, 95% CI: 0.21, 0.81, P= 0.004). The OR for stool clearance was lower with nitazoxanide and azithromycin than monotherapy (OR 0.27, 95% CI: 0.01, 5.77), but P=0.24, which means not statistically significant.
Read full abstract